美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.32

0.0000

成交量：11

成交額：368.57

市值：1,332.60萬

市盈率：- -

高：33.32

開：33.32

低：33.32

收：33.32

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.30

換手率：0.00%

股息：0.08

股息率：0.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段

邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗

諾華DM1藥物III期臨床試驗未達到主要終點

石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動

石藥集團：SYH2085片II期臨床試驗在中國正式啓動

繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗

恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書

諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。

恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗

智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准

恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准

恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准

南方财经网

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批目前國內尚無流感病毒mRNA疫苗產品獲批上市

智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准

華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准

甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣

2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BMED/news?page=6"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.315,"timestamp":1789565996832,"preClose":33.315,"halted":0,"volume":11,"delay":0,"changeRate":0,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-16 09:41:28 EDT","open":33.315,"high":33.315,"low":33.315,"amount":368.57183,"amplitude":0,"askPrice":33.61,"askSize":1000,"bidPrice":33.54,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.315,"sharesOutstanding":360000,"nav":33.210436,"aum":13284174.4,"dividendRate":0.002392,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.23,"preClose":33.315,"latestTime":"16:10 EDT","volume":6,"amount":199.89,"timestamp":1789503006991,"change":-0.085,"changeRate":-0.002551,"amplitude":0},"volumeRatio":0.304618,"impliedVol":0.0634,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.304618,"shares":400000,"dividePrice":0.0797,"high":33.315,"amplitude":0,"preClose":33.315,"low":33.315,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.315,"eps":0,"divideRate":0.002392,"volume":11,"delay":0,"ttmEps":0,"open":33.315,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.0422,"twentyDayClose":32.666,"sixtyDayClose":28.5621},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:6,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665323037","title":"邁普醫學(301033.SZ)：「可吸收止血流體明膠」進入臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665323037","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665323037?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:21","pubTimestamp":1788855709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈普医学(301033.SZ)发布公告，公司的研发项目“可吸收止血流体明胶”于近期正式进入临床试验阶段。该医疗器械临床用途：在外科手术中，当压迫、结扎、电凝或其他传统的止血方法无法控制小动脉、静脉及毛细血管的出血，或上述方法无法操作时，可使用可吸收止血流体明胶进行辅助止血。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","301033","IBBJ","BMED","BK0251","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665332349","title":"邁普醫學：可吸收止血流體明膠作為第三類醫療器械進入臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665332349","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665332349?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:14","pubTimestamp":1788855283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDEV","AGNG","IBBQ","LGHT","LNGR","RSPH","IEIH","GDOC","HART","BMED","MDTX","PTH","MEDX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665342373","title":"諾華DM1藥物III期臨床試驗未達到主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2665342373","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665342373?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 13:31","pubTimestamp":1788845477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PPH","BK4588","BK4578","LU0070302665.USD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IBBQ","BMED","PSYK","NVS","MDTX","BK4585","IBBJ","IE00BJT1NW94.SGD","BK4532","IE00BJJMRZ35.SGD","BK4007","IE00B2B36J28.USD","LU0320765489.SGD","LU0208291251.USD","IE0009355771.USD","LU0211331839.USD","IE0002141913.USD","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319978","title":"石藥集團(01093)：SYH2085片用於治療成人單純性流感的II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319978","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319978?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:30","pubTimestamp":1788780616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的SYH2085片用于治疗成人无并发症的单纯性流行性感冒的II期临床试验已于中国首家中心正式启动。此前，集团已于2025年12月获中国国家药品监督管理局就该产品签发的《药物临床试验批准通知书》。本次启动的该产品临床试验为多中心、随机、双盲、安慰剂对照的II期临床研究，旨在评价该产品治疗中国成人无并发症的单纯性流行性感冒参与者中的有效性及安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1191","LU1951186391.HKD","LU1807302812.USD","IE0008368742.USD","LU0326950275.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B543WZ88.USD","IBBQ","IE00BZ08YR35.GBP","BMED","LU0072913022.USD","LU0501845795.SGD","LU1226288170.HKD","LU1008478684.HKD","PSYK","LU2039709279.SGD","MDTX","LU1226287875.USD","IBBJ","IE00B031HY20.USD","BK1521","LU0315179316.USD","01093","LU1226287529.USD","LU1328277881.USD","KURE","LU0067412154.USD","LU0140636845.USD","LU1152091168.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008369823.USD","LU0314109678.HKD","LU1993786604.SGD","HK0000165453.HKD","LU1152091754.HKD","LU0880133367.SGD","BK1515","LU1960683339.HKD","LU1813983027.USD","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665319936","title":"石藥集團：SYH2085片II期臨床試驗在中國正式啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2665319936","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665319936?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:28","pubTimestamp":1788780492,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","BMED","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831989","title":"繼諾華之後，諾和諾德(NVO.US)終止兩項心血管臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831989","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831989?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 19:10","pubTimestamp":1788779458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0002141913.USD","BK4585","BMED","LU0211331839.USD","BK4532","MDTX","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4588","BK4578","IE00B4R5TH58.HKD","MEDX","IBBQ","IE00B2B36J28.USD","LU0320765489.SGD","BGIA","IBBJ","PPH","PSYK","LU0070302665.USD","BK4007","NVS","LU0208291251.USD","IE00BJJMRZ35.SGD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665031616","title":"恒瑞醫藥(01276)：SHR-1179注射液獲得藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2665031616","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665031616?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:49","pubTimestamp":1788778166,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，近日，江苏恒瑞医药股份有限公司(以下简称“公司”)子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于 SHR-1179 注射液的《药物临床试验批准通知书》，将于近期开展临床试验。SHR-1179 注射液是公司自主研发的治疗用 1 类生物制品，拟用于体重管理适应症，国内外暂无相同靶点药物获批上市。截至目前，SHR-1179 注射液相关项目累计研发投入约2,420万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492927.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1191","LU0359201612.USD","BK0239","LU0359202008.SGD","600276","BK0012","LU1064130708.USD","LU1655091616.SGD","LU1969619763.USD","LU0405327148.USD","LU1997244956.HKD","LU2289578879.USD","LU1580142542.USD","LU0359201885.HKD","LU1023057109.AUD","LU1328615791.USD","LU1146622755.USD","LU2097828631.EUR","LU2495084118.USD","IBBQ","BMED","PSYK","LU2543165471.USD","LU2580892789.USD","BK0188","01276","MDTX","LU1064131003.USD","IBBJ","BK0183","LU1255011170.USD","LU2148510915.USD","LU2097828474.EUR","LU1997245177.USD","LU1997245094.SGD","LU2580892862.HKD","LU1820825898.SGD","BK0196","LU1781817850.SGD","LU2097828714.EUR","LU0405327494.USD","BK0060","LU2097828557.USD","LU2328871848.SGD","LU2097828805.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315689","title":"諾和諾德再次暫停了其實驗性心臟病藥物的兩項臨床試驗，進一步打擊了該藥的發展前景。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315689","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:02","pubTimestamp":1788775332,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","MDTX","PSYK","BGIA","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313519","title":"恒瑞醫藥(600276.SH)子公司HRS-1597片獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313519?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:18","pubTimestamp":1788772689,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司山东盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS-1597片的《药物临床试验批准通知书》，将于近期开展临床试验。HRS-1597片是公司自主研发的1类新药，拟用于体重管理。经查询，目前国内外暂无同类药物获批上市。截至目前，HRS-1597片相关项目累计研发投入约1690万元(未经审计)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201612.USD","LU1997244956.HKD","BMED","BK1191","LU1146622755.USD","LU2097828474.EUR","LU2495084118.USD","LU1064130708.USD","LU2097828714.EUR","BK0012","LU0405327494.USD","LU1064131003.USD","LU2328871848.SGD","LU2148510915.USD","LU2488822045.USD","LU1655091616.SGD","LU2097828631.EUR","BK0060","LU0405327148.USD","LU1781817850.SGD","LU2289578879.USD","LU1023057109.AUD","BK0196","LU2580892789.USD","IBBQ","LU2097828557.USD","PSYK","LU1997245094.SGD","LU1997245177.USD","IBBJ","01276","LU0359202008.SGD","LU2543165471.USD","LU1820825898.SGD","LU1328615791.USD","600276","BK0239","MDTX","LU2580892862.HKD","LU1580142542.USD","BK0028","LU2097828805.USD","LU1969619763.USD","BK0183","LU0359201885.HKD","LU1255011170.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665313385","title":"智飛生物(300122.SZ)：重組輪狀病毒亞單位疫苗(大腸桿菌)獲得臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665313385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665313385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 17:15","pubTimestamp":1788772542,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由全资子公司北京智飞绿竹生物制药有限公司研发的重组轮状病毒亚单位疫苗获得国家药品监督管理局药物临床试验批准通知书，同意开展预防轮状病毒感染引起的急性胃肠炎的临床试验。公司的重组轮状病毒亚单位疫苗采用重组大肠杆菌发酵、纯化等工艺，获得三种基因型的重组VP8蛋白，经佐剂吸附制备成疫苗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU1064130708.USD","BK0077","BK0196","BMED","LU1064131003.USD","BK0046","LU2580892789.USD","300122","IBBQ","BK0188","MDTX","159646","PSYK","BK0239","IBBJ","LU2580892862.HKD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665831854","title":"恒瑞醫藥：子公司HRS-1597片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665831854","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665831854?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770825,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","BMED","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665181063","title":"恒瑞醫藥：HRS-6209膠囊、HRS-4508片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665181063","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665181063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:47","pubTimestamp":1788770820,"startTime":"0","endTime":"0","summary":"南财智讯9月7日电，恒瑞医药公告，HRS-6209胶囊、HRS-4508片收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展临床试验。通知书明确：HRS-6209联合其他抗肿瘤治疗在晚期不可切除或转移性乳腺癌，或HRS-9813在晚期实体瘤患者中的安全性、耐受性、药代动力学及初步疗效的开放、多中心Ib/II期临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866721614.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866721614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828631.EUR","LU1997245177.USD","BK0028","BK0188","IBBQ","LU2580892789.USD","IBBJ","LU1997245094.SGD","LU1781817850.SGD","LU1997244956.HKD","LU1655091616.SGD","LU0359202008.SGD","LU2543165471.USD","LU2488822045.USD","BK0183","LU0405327148.USD","LU1023057109.AUD","BMED","LU2097828474.EUR","LU2097828805.USD","01276","BK0196","BK0060","LU2097828714.EUR","LU2495084118.USD","PSYK","LU1064130708.USD","LU0359201612.USD","LU2148510915.USD","LU2580892862.HKD","MDTX","LU1820825898.SGD","LU1146622755.USD","LU1328615791.USD","LU1064131003.USD","LU2097828557.USD","BK0239","LU1969619763.USD","600276","LU2328871848.SGD","BK1191","LU1255011170.USD","LU1580142542.USD","LU2289578879.USD","BK0012","LU0359201885.HKD","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665550318","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665550318","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665550318?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华兰疫苗 发布公告，公司于近日收到国家药品监督管理局核准签发的关于新型流感病毒mRNA疫苗的《药物临床试验批准通知书》。公司研发的新型流感病毒mRNA疫苗采用mRNA技术路线，通过递送编码流感病毒相关抗原的mRNA，在体内表达相应抗原并诱导机体产生免疫应答。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IPOS","MRNX","IBBQ","PSYK","BMED","MDTX","301207","MRNY","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318561","title":"華蘭疫苗(301207.SZ)：新型流感病毒mRNA疫苗臨床試驗獲批 目前國內尚無流感病毒mRNA疫苗產品獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318561","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665318561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:42","pubTimestamp":1788770526,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IPOS","IBBQ","MRNX","BMED","IBBJ","MDTX","PSYK","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665188143","title":"智飛生物：重組輪狀病毒亞單位疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665188143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665188143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:38","pubTimestamp":1788770300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BMED","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665390071","title":"華蘭疫苗：新型流感病毒mRNA疫苗獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665390071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665390071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:37","pubTimestamp":1788770253,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","MRNY","IBBJ","MRNX","PSYK","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665397088","title":"甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603087","PSYK","IBBQ","BK0239","BMED","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","APXH","09939","XLVI","PBPH","BMED","BK1574","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665636842","title":"「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣","url":"https://stock-news.laohu8.com/highlight/detail?id=2665636842","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665636842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 16:59","pubTimestamp":1788598790,"startTime":"0","endTime":"0","summary":"9月5日早上8时，2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作在北京市西城区全国人大会议中心启动，时代周报记者前往现场了解情况。谈判开始之前，已有数十名药企代表在全国人大会议中心门口等候。8时左右，国家医保局工作人员在会议中心门口点名药企代表进入，8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866015465.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866015465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","PBPH","XLVI","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665712357","title":"2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2665712357","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665712357?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 09:47","pubTimestamp":1788572828,"startTime":"0","endTime":"0","summary":"本文来源：时代周报2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作，于9月5日早8点在北京市西城区全国人大会议中心启动。时代周报记者从现场了解到，早8点左右，国家医保局工作人员开始在会议中心门口点名药企代表进入；8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865981910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865981910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLVI","BMED","APXH","PBPH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}